Novavax Inc. ^Company

Novavax creates recombinant protein nanoparticle vaccines to address a broad range of infectious diseases. Novavax, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies. In April, the company said it had identified a COVID-19 vaccine candidate, and it plans to initiate a Phase I clinical study in May. The first phase of the placebo-controlled study will enroll 130 healthy adults; the first round of data from that study is expected in July. In March the company said it had received $4 million from CEPI to develop a COVID-19 vaccine and that Emergent BioSolutions Inc. EBS, +4.52% would support contract development and manufacturing for the experimental vaccine.